JOHNSON & JOHNSON

NYSE: JNJ (Johnson & Johnson)

最近更新时间: 23分钟之前

154.77

1.14 (0.74%)

  • 1天 0.74%
  • 5天 -0.28%
  • 1月 0.19%
  • 6月 3.66%
  • 今年至今天 7.46%
  • 1年 5.70%
  • 5年 5.45%
前收盘价格 153.63
收盘价格 154.00
成交量 2,476,358
平均成交量 (3个月) 9,317,871
市值 372,387,479,552
市盈率 (P/E TTM) 17.22
预期市盈率 (P/E Forward) 14.75
价格/销量 (P/S) 4.18
股市价格/股市净资产 (P/B) 4.73
52周波幅
140.68 (-9%) — 169.99 (9%)
利润日期 16 Jul 2025
股息率 (DY TTM) 2.40%
营业毛利率 24.42%
营业利益率 (TTM) 29.41%
稀释每股收益 (EPS TTM) 8.99
季度收入增长率 (YOY) 2.40%
季度盈利增长率 (YOY) 237.90%
总债务/股东权益 (D/E MRQ) 66.90%
流动比率 (MRQ) 1.26
营业现金流 (OCF TTM) 24.78 B
杠杆自由现金流 (LFCF TTM) 16.80 B
资产报酬率 (ROA TTM) 7.77%
股东权益报酬率 (ROE TTM) 29.45%

市场趋势

短期 中期
行业 Drug Manufacturers - General (US) 看跌 混合的
Drug Manufacturers - General (全球的) 看跌 混合的
股票 Johnson & Johnson 看跌 看跌

AIStockmoo 评分

0.6
分析师共识 -0.5
内部交易活动 NA
价格波动 1.0
技术平均移动指标 0.0
技术振荡指标 2.0
平均 0.63

相关股票

股票 市值 DY P/E（TTM） P/B
JNJ 372 B 2.40% 17.22 4.73
ABBV 321 B 3.51% 77.36 229.94
PFE 133 B 5.43% 16.96 1.45
BMY 96 B 3.87% 17.54 5.61
GSK 84 B 2.77% 20.16 4.57
LLY 662 B 0.56% 59.88 45.23

Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.
部门 Healthcare
行业 Drug Manufacturers - General
投资方式 Large Value
内部持股比例 0.06%
机构持股比例 73.38%
52周波幅
140.68 (-9%) — 169.99 (9%)
目标价格波幅
153.00 (-1%) — 181.00 (16%)
高 181.00 (RBC Capital, 16.95%) 购买
中 165.00 (6.61%)
低 153.00 (Leerink Partners, -1.14%) 保留
平均值 166.14 (7.35%)
总计 3 购买, 4 保留
平均价格@调整类型 152.44
公司 日期 目标价格 调整类型 价格@调整类型
RBC Capital 05 Jun 2025 181.00 (16.95%) 购买 153.66
16 Apr 2025 181.00 (16.95%) 购买 153.91
Leerink Partners 13 May 2025 153.00 (-1.14%) 保留 148.44
Barclays 17 Apr 2025 165.00 (6.61%) 保留 157.47
Morgan Stanley 16 Apr 2025 169.00 (9.19%) 保留 153.91
09 Apr 2025 164.00 (5.96%) 保留 150.97
Raymond James 16 Apr 2025 164.00 (5.96%) 购买 153.91
14 Apr 2025 162.00 (4.67%) 购买 154.36
B of A Securities 10 Apr 2025 159.00 (2.73%) 保留 148.69
Goldman Sachs 09 Apr 2025 172.00 (11.13%) 购买 150.97

该时间范围内无数据。

  • 3M
日期 类型 细节
03 Jun 2025 公告 Johnson & Johnson leads with first PARP inhibitor combo to improve efficacy in patients with HRR-altered mCSPC
03 Jun 2025 公告 DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based regimen shows 95 percent progression-free survival at four years in transplant-eligible, newly diagnosed patients with multiple myeloma who achieved sustained MRD negativity
03 Jun 2025 公告 Single infusion of CARVYKTI® (ciltacabtagene autoleucel) delivered lasting treatment-free remissions for at least five years in patients with relapsed or refractory multiple myeloma
03 Jun 2025 公告 Early results from Johnson & Johnson's trispecific antibody show promising response in heavily pretreated multiple myeloma patients
28 May 2025 公告 Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results
23 May 2025 公告 FDA Panel Reiterates the Cancer Risks of Talc
21 May 2025 公告 Johnson & Johnson to Participate in the Bernstein’s 41st Annual Strategic Decisions Conference
20 May 2025 公告 Dean Omar Branham Shirley Recognized Twice Among ALM’s 2024 Top 100 Verdicts
20 May 2025 公告 U.S. FDA Oncologic Drugs Advisory Committee votes in favor of the benefit-risk profile of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for high-risk smoldering multiple myeloma
18 May 2025 公告 Statement On $147M Verdict for AMDR Member Innovative Health Against Johnson & Johnson’s Biosense Webster Medical Technology Unit
15 May 2025 公告 Nachawati Law Group Files New Ovarian Cancer Lawsuits Against Johnson & Johnson After Latest Bankruptcy Ploy Fails
14 May 2025 公告 Johnson & Johnson to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
12 May 2025 CNBC Trump signs order aiming to cut some U.S. drug prices to match lower ones abroad
09 May 2025 公告 Icotrokinra results show significant skin clearance in patients with difficult-to-treat scalp and genital psoriasis
08 May 2025 公告 Johnson & Johnson expands efforts to champion the nursing workforce globally
05 May 2025 公告 TREMFYA® (guselkumab) positioned to become the first and only IL-23 inhibitor to offer subcutaneous induction in ulcerative colitis as demonstrated in new data through 24 weeks
05 May 2025 公告 TREMFYA® (guselkumab) delivers sustained clinical and endoscopic remission in ulcerative colitis through two years
05 May 2025 CNBC Trump signs order to boost domestic drug manufacturing as pharma tariffs loom
30 Apr 2025 公告 Johnson & Johnson receives FDA approval for IMAAVY™ (nipocalimab-aahu), a new FcRn blocker offering long-lasting disease control in the broadest population of people living with generalized myasthenia gravis (gMG)
28 Apr 2025 公告 Johnson & Johnson to Participate in the Bernstein’s 41st Annual Strategic Decisions Conference
26 Apr 2025 公告 Johnson & Johnson's TAR-200 monotherapy achieves high disease-free survival of more than 80 percent in BCG-unresponsive, high-risk papillary NMIBC
26 Apr 2025 公告 Johnson & Johnson's TAR-200 monotherapy demonstrates highest complete response rate with sustained clinical benefits in patients with certain types of bladder cancer
24 Apr 2025 CNBC Corporate America shelled out millions for Trump's inauguration. Now he's upending many of their businesses
21 Apr 2025 公告 Johnson & Johnson unveils highly anticipated and potential practice-changing data in bladder cancer treatment at AUA
16 Apr 2025 公告 Johnson & Johnson to Participate in the 2025 RBC Capital Markets Global Healthcare Conference
16 Apr 2025 CNBC Medical product manufacturers are divided over Trump's tariffs
15 Apr 2025 公告 Johnson & Johnson Announces 63rd Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 4.8%
15 Apr 2025 公告 Johnson & Johnson Reports Q1 2025 Results
11 Apr 2025 CNBC Trump's pharmaceutical tariffs could raise costs for patients, worsen drug shortages
10 Apr 2025 公告 Icotrokinra results show 75% of adolescents with plaque psoriasis achieved completely clear skin and demonstrate favorable safety profile in a once daily pill
09 Apr 2025 CNBC Pharmaceutical stocks rise as Trump pauses tariffs but not for China
08 Apr 2025 公告 Johnson & Johnson highlights new data that showcase the strength of nipocalimab, demonstrating long-term sustained disease control in adults living with generalized myasthenia gravis (gMG)
07 Apr 2025 公告 Johnson & Johnson to Participate in the BofA Securities 2025 Healthcare Conference
04 Apr 2025 公告 TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to significantly reduce both the signs and symptoms and the progression of structural damage in adults living with active psoriatic arthritis
02 Apr 2025 公告 Johnson & Johnson Closes Landmark Intra-Cellular Therapies, Inc. Acquisition to Solidify Neuroscience Leadership
01 Apr 2025 公告 Johnson & Johnson Announces Expected Closing Date for Intra-Cellular Acquisition
01 Apr 2025 公告 Federal Judge Rejects Johnson & Johnson Bankruptcy Strategy, Paving Way for Talc Victims to Seek Justice in Trial Courts
26 Mar 2025 公告 RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) outperforms osimertinib with a significant and unprecedented overall survival benefit in patients with EGFR-mutated non-small cell lung cancer
26 Mar 2025 公告 New nipocalimab data and real-world research at AAN 2025 highlight positive Phase 3 results and commitment to people living with generalized myasthenia gravis (gMG)
21 Mar 2025 公告 Johnson & Johnson Increases U.S. Investment to More than $55 Billion Over the Next Four Years
20 Mar 2025 公告 RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) significantly outperforms standard of care in first-line EGFR-mutated lung cancer with compelling new data at ELCC 2025
20 Mar 2025 公告 U.S. FDA approves TREMFYA® (guselkumab), the first and only IL-23 inhibitor offering both subcutaneous and intravenous induction options, for adult patients with moderately to severely active Crohn's disease
18 Mar 2025 公告 Nipocalimab, the first and only investigational treatment to be granted U.S. FDA Breakthrough Therapy designation for the treatment of adults with moderate-to-severe Sjögren's disease, has now received Fast Track designation
10 Mar 2025 公告 Icotrokinra meets primary endpoint of clinical response in ulcerative colitis study and shows potential to transform the treatment paradigm for patients
08 Mar 2025 公告 Icotrokinra results show potential to set a new standard of treatment in plaque psoriasis
显示更多
股息率 (DY TTM) 2.40%
5年平均股息收益率 2.78%
股息支付比率 55.17%
预计下次股息支付 Sep 2025
除息日 公告日期 支付日期 详情
18 Feb 2025 02 Jan 2025 04 Mar 2025 1.24 现金
26 Nov 2024 15 Oct 2024 10 Dec 2024 1.24 现金
27 Aug 2024 17 Jul 2024 10 Sep 2024 1.24 现金
20 May 2024 16 Apr 2024 04 Jun 2024 1.24 现金
16 Feb 2024 02 Jan 2024 05 Mar 2024 1.19 现金
20 Nov 2023 19 Oct 2023 05 Dec 2023 1.19 现金
25 Aug 2023 20 Jul 2023 07 Sep 2023 1.19 现金
22 May 2023 18 Apr 2023 06 Jun 2023 1.19 现金
17 Feb 2023 03 Jan 2023 07 Mar 2023 1.13 现金
21 Nov 2022 19 Oct 2022 06 Dec 2022 1.13 现金
22 Aug 2022 18 Jul 2022 06 Sep 2022 1.13 现金
23 May 2022 19 Apr 2022 07 Jun 2022 1.13 现金
18 Feb 2022 04 Jan 2022 08 Mar 2022 1.06 现金
22 Nov 2021 21 Oct 2021 07 Dec 2021 1.06 现金
23 Aug 2021 19 Jul 2021 07 Sep 2021 1.06 现金
24 May 2021 06 May 2021 08 Jun 2021 1.06 现金
22 Feb 2021 04 Jan 2021 09 Mar 2021 1.01 现金
23 Nov 2020 22 Oct 2020 08 Dec 2020 1.01 现金
24 Aug 2020 20 Jul 2020 08 Sep 2020 1.01 现金
22 May 2020 14 Apr 2020 09 Jun 2020 1.01 现金
24 Feb 2020 02 Jan 2020 10 Mar 2020 0.95 现金
25 Nov 2019 18 Oct 2019 10 Dec 2019 0.95 现金
26 Aug 2019 16 Jul 2019 10 Sep 2019 0.95 现金
24 May 2019 26 Apr 2019 11 Jun 2019 0.95 现金
25 Feb 2019 02 Jan 2019 12 Mar 2019 0.9 现金
26 Nov 2018 18 Oct 2018 11 Dec 2018 0.9 现金
27 Aug 2018 17 Jul 2018 11 Sep 2018 0.9 现金
25 May 2018 26 Apr 2018 12 Jun 2018 0.9 现金
26 Feb 2018 02 Jan 2018 13 Mar 2018 0.84 现金
27 Nov 2017 19 Oct 2017 12 Dec 2017 0.84 现金
25 Aug 2017 17 Jul 2017 12 Sep 2017 0.84 现金
25 May 2017 27 Apr 2017 13 Jun 2017 0.84 现金
24 Feb 2017 03 Jan 2017 14 Mar 2017 0.8 现金
18 Nov 2016 20 Oct 2016 06 Dec 2016 0.8 现金
19 Aug 2016 18 Jul 2016 06 Sep 2016 0.8 现金
20 May 2016 28 Apr 2016 07 Jun 2016 0.8 现金
19 Feb 2016 04 Jan 2016 08 Mar 2016 0.75 现金
20 Nov 2015 22 Oct 2015 08 Dec 2015 0.75 现金
21 Aug 2015 20 Jul 2015 08 Sep 2015 0.75 现金
21 May 2015 23 Apr 2015 09 Jun 2015 0.75 现金
20 Feb 2015 05 Jan 2015 10 Mar 2015 0.7 现金
21 Nov 2014 16 Oct 2014 09 Dec 2014 0.7 现金
22 Aug 2014 21 Jul 2014 09 Sep 2014 0.7 现金
22 May 2014 24 Apr 2014 10 Jun 2014 0.7 现金
21 Feb 2014 02 Jan 2014 11 Mar 2014 0.66 现金
22 Nov 2013 17 Oct 2013 10 Dec 2013 0.66 现金
23 Aug 2013 15 Jul 2013 10 Sep 2013 0.66 现金
23 May 2013 25 Apr 2013 11 Jun 2013 0.66 现金
22 Feb 2013 02 Jan 2013 12 Mar 2013 0.61 现金
23 Nov 2012 17 Oct 2012 11 Dec 2012 0.61 现金
24 Aug 2012 16 Jul 2012 11 Sep 2012 0.61 现金
24 May 2012 26 Apr 2012 12 Jun 2012 0.61 现金
24 Feb 2012 03 Jan 2012 13 Mar 2012 0.57 现金
25 Nov 2011 21 Oct 2011 13 Dec 2011 0.57 现金
26 Aug 2011 18 Jul 2011 13 Sep 2011 0.57 现金
26 May 2011 28 Apr 2011 14 Jun 2011 0.57 现金
25 Feb 2011 03 Jan 2011 15 Mar 2011 0.54 现金
26 Nov 2010 21 Oct 2010 14 Dec 2010 0.54 现金
27 Aug 2010 19 Jul 2010 14 Sep 2010 0.54 现金
27 May 2010 22 Apr 2010 15 Jun 2010 0.54 现金
19 Feb 2010 04 Jan 2010 09 Mar 2010 0.49 现金
20 Nov 2009 22 Oct 2009 08 Dec 2009 0.49 现金
21 Aug 2009 20 Jul 2009 08 Sep 2009 0.49 现金
21 May 2009 23 Apr 2009 09 Jun 2009 0.49 现金
20 Feb 2009 05 Jan 2009 10 Mar 2009 0.46 现金
21 Nov 2008 16 Oct 2008 09 Dec 2008 0.46 现金
22 Aug 2008 21 Jul 2008 09 Sep 2008 0.46 现金
22 May 2008 24 Apr 2008 10 Jun 2008 0.46 现金
22 Feb 2008 02 Jan 2008 11 Mar 2008 0.415 现金
23 Nov 2007 18 Oct 2007 11 Dec 2007 0.415 现金
24 Aug 2007 16 Jul 2007 11 Sep 2007 0.415 现金
24 May 2007 26 Apr 2007 12 Jun 2007 0.415 现金
23 Feb 2007 03 Jan 2007 13 Mar 2007 0.375 现金
24 Nov 2006 19 Oct 2006 12 Dec 2006 0.375 现金
25 Aug 2006 18 Jul 2006 12 Sep 2006 0.375 现金
25 May 2006 27 Apr 2006 13 Jun 2006 0.375 现金
18 Nov 2005 20 Oct 2005 13 Dec 2005 0.33 现金
19 Aug 2005 18 Jul 2005 13 Sep 2005 0.33 现金
13 May 2005 28 Apr 2005 07 Jun 2005 0.33 现金
11 Feb 2005 04 Jan 2005 08 Mar 2005 0.285 现金
12 Nov 2004 22 Oct 2004 07 Dec 2004 0.285 现金
13 Aug 2004 20 Jul 2004 07 Sep 2004 0.285 现金
14 May 2004 22 Apr 2004 08 Jun 2004 0.285 现金
12 Feb 2004 05 Jan 2004 09 Mar 2004 0.24 现金
14 Nov 2003 16 Oct 2003 09 Dec 2003 0.24 现金
15 Aug 2003 22 Jul 2003 09 Sep 2003 0.24 现金
16 May 2003 24 Apr 2003 10 Jun 2003 0.24 现金
13 Feb 2003 06 Jan 2003 11 Mar 2003 0.205 现金
15 Nov 2002 15 Oct 2002 10 Dec 2002 0.205 现金
16 Aug 2002 15 Jul 2002 10 Sep 2002 0.205 现金
17 May 2002 25 Apr 2002 11 Jun 2002 0.205 现金
14 Feb 2002 02 Jan 2002 12 Mar 2002 0.18 现金
16 Nov 2001 18 Oct 2001 11 Dec 2001 0.18 现金
17 Aug 2001 16 Jul 2001 11 Sep 2001 0.18 现金
18 May 2001 26 Apr 2001 12 Jun 2001 0.36 现金
15 Feb 2001 02 Jan 2001 13 Mar 2001 0.32 现金
17 Nov 2000 16 Oct 2000 12 Dec 2000 0.32 现金
18 Aug 2000 17 Jul 2000 12 Sep 2000 0.32 现金
19 May 2000 19 Apr 2000 13 Jun 2000 0.32 现金
11 Feb 2000 03 Jan 2000 07 Mar 2000 0.28 现金
12 Nov 1999 18 Oct 1999 07 Dec 1999 0.28 现金
13 Aug 1999 19 Jul 1999 07 Sep 1999 0.28 现金
14 May 1999 22 Apr 1999 08 Jun 1999 0.28 现金
11 Feb 1999 04 Jan 1999 09 Mar 1999 0.25 现金
13 Nov 1998 19 Oct 1998 08 Dec 1998 0.25 现金
14 Aug 1998 20 Jul 1998 08 Sep 1998 0.25 现金
15 May 1998 23 Apr 1998 09 Jun 1998 0.25 现金
12 Feb 1998 02 Jan 1998 10 Mar 1998 0.22 现金
14 Nov 1997 20 Oct 1997 09 Dec 1997 0.22 现金
15 Aug 1997 21 Jul 1997 09 Sep 1997 0.22 现金
16 May 1997 24 Apr 1997 10 Jun 1997 0.22 现金
13 Feb 1997 02 Jan 1997 11 Mar 1997 0.19 现金
15 Nov 1996 21 Oct 1996 10 Dec 1996 0.19 现金
16 Aug 1996 15 Jul 1996 10 Sep 1996 0.19 现金
17 May 1996 25 Apr 1996 11 Jun 1996 0.38 现金
15 Feb 1996 02 Jan 1996 12 Mar 1996 0.33 现金
10 Nov 1995 16 Oct 1995 05 Dec 1995 0.33 现金
11 Aug 1995 17 Jul 1995 05 Sep 1995 0.33 现金
10 May 1995 27 Apr 1995 06 Jun 1995 0.33 现金
显示更多

每年股息收益率

年份 每年总股息 ($) 频率/年份 收益率 %
2025 1.24 1 0.80
2024 4.91 4 3.40
2023 4.70 4 3.00
2022 4.45 4 2.52
2021 4.19 4 2.45
2020 3.98 4 2.53
2019 3.75 4 2.57
2018 3.54 4 2.74
2017 3.32 4 2.38
2016 3.15 4 2.73
2015 2.95 4 2.87
2014 2.76 4 2.64
2013 2.59 4 2.83
2012 2.40 4 3.42
2011 2.25 4 3.43
2010 2.11 4 3.41
2009 1.93 4 3.00
2008 1.80 4 3.00
2007 1.62 4 2.43
2006 1.13 3 1.70
2005 1.28 4 2.12
2004 1.10 4 1.73
2003 0.925 4 1.79
2002 0.795 4 1.48
2001 1.04 4 1.76
2000 1.24 4 2.36
1999 1.09 4 2.34
1998 0.970 4 2.31
1997 0.850 4 2.58
1996 1.09 4 4.38
1995 0.990 3 4.63
显示更多

支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。

投资组合

AI 建议策略模板

自定义的价格提醒

风险概况

| | | | |
很保守
适度保守
中等
中等风险
激进风险
安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)

免责声明：以上内容仅供参考，并非投资建议。请咨询合格的财务顾问。

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

52周波幅范围
 
52WL
 
52WH
SL
EP
TP1
TP2

所有提醒价格都在52周波幅范围内

已实现利润 -
未实现利润 -
收到股息 2025 -
利润总额 -
平均回报 -
数量(购买) -
平均价格(购买) -
数量(卖出) -
平均价格(卖出) -
没有符合您标准的股票